Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG) (CSREIG)
Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas (inSituVac2)(CSREIG)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Peijuan Ren, M.D.
- Phone Number: +861059978039
- Email: ttyyirb@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100050
- Recruiting
- Beijing Tiantan Hospital
-
Contact:
- Song Lin, M.D.
- Phone Number: 861059976509
- Email: linsong2005@126.com
-
Contact:
- Xiaohui Ren, M.D.
- Phone Number: +861059976509
- Email: xiaohuiren@aliyun.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. Histopathologically confirmed rGBM
- 2. Age18-65
- 3. Participants had undergone maximal surgical resection
- 4. Amount of dexamethasone was not more than 2mg/ days
- 5. Ability and willingness to sign informed consent
- 6. Karnofsky Performance Score of 70 or more
- 7. Normal liver and kidney function
- 8. Not accepted other treatment plan during the immunotherapy
Exclusion Criteria:
- 1. Not conforming to the standard
- 2. Systemic illness or medical condition may pose additional risk,including cardiac, incompensated renal or liver function abnormalities;inflammatory and immune system diseases of rheumatic arthritis
- 3. Received other drugs for glioma therapy 60 days before participated
- 4. Allergy to immune adjuvant
- 5. Nervous system disease and diffuse leptomeningeal disease
- 6. Amount of dexamethasone was more than 2mg/days during the immunotherapy
- 7. Pregnant or lactation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: rGBM Group with combined stereotactic radiosurgery and enhanced immunotherapy
Patients with rGBMs will receive combined stereotactic radiosurgery and enhanced immunal adjuvants (GM-CSF, Sapylin, MnCl2).
The safety and efficacy will be analyzed.
|
Patients will be administrated immunal adjuvants intratumorally and systemically with concurrent stereotactic radiosurgery.
Other Names:
|
|
No Intervention: rGBM Group with
After biopsy or tumor resection, this rGBM group was treated with FDA-approved strategies proposed by the MDT group.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Treatment-related Adverse Events
Time Frame: 2 years
|
Adverse events during and after the combined treatment
|
2 years
|
|
Progression-free Survival
Time Frame: 2 years
|
Disease progression free survival time after combined treatment
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
overall survival
Time Frame: 2 years
|
Overall survival time after the combined treatment
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Song Lin, M.D., Beijing Tiantan Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- B0012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.